汇宇制药：公司产品获得意大利、挪威的上市许可

Core Viewpoint - The company has received marketing approvals for its injectable paclitaxel (albumin-bound) product from both the Italian Medicines Agency and the Norwegian Medicines Agency [1] Group 1 - The subsidiary Seacross (Europe) Pharma Ltd. is responsible for the recent approvals [1] - The approvals signify a significant step for the company's product in the European market [1]